The Effect of the Synergistic Combination of Vitamin D and Doxorubicin on the MCF-7 Line Breast Cancer Cells ^†

Breast cancer is the most prevalent cancer in the female population. The prolonged action of estrogen may affect tumor proliferation. Additionally, a fat-rich diet may have various effects on cancer proliferation, depending on the type of fat. Vitamin D, similarly to estrogen, is a fat-soluble cholesterol derivative. The deficiency of vitamin D correlates with an increased proliferation of breast cancer cells. In turn, doxorubicin is commonly used as a cytostatic in chemotherapy. The study aimed to assess whether vitamin D enhances the anticancer effect of doxorubicin (DOX) in the MCF-7 cell line. The cells were divided into four groups: untreated control, DOX- and vitamin D-treated cells, and cells treated with the combination of compounds in a 1:1 ratio. We applied the MTT colorimetric assay (cell viability analysis), Annexin V/PI assay (cell death analysis), flow cytometry (cell cycle distribution), and fluorescence staining of cytoskeletal proteins (F-actin and vimentin). The type of DOX and vitamin D interaction was estimated based on the Chou–Talalay method. Our results showed that vitamin D and doxorubicin in a 1:1 ratio act synergistically. We observed a decrease in the survival of MCF7 cells. The combination of DOX and vitamin D enhanced the changes in morphology and organization in F-actin and the vimentin network compared to the treatment with the substances separately. In summary, we suggest that natural compounds such as vitamin D may be useful in anticancer treatment in the context of enhancing the cytostatic effects of drugs.